Palatin Technologies Inc Liquidation Value Calculator
Palatin Technologies Inc
Current Price: N/A
Loading calculator data...
Advanced: All 82 XBRL Tags
Every XBRL tag from SEC EDGAR filings, grouped by financial statement type. total = may include children, fact = independent leaf value.
Balance Sheet
| Tag | Value | Unit | ||
|---|---|---|---|---|
| accounts_payable | ||||
| Accounts Payable Current total AccountsPayableCurrent |
$5.45M | USD | ||
| AI Insight · Accounts payable of $5.5M represents the largest single liability line and must be settled at face value in a liquidation. This balance is elevated and likely includes the $3.8M Altanispac sublicense deferred consideration that the filing states is reflected in current liabilities as of December 31, 2025. If the $3.8M is embedded here, the underlying trade AP is approximately $1.6M—still material but a different risk profile. The filing does not separately XBRL-tag the Altanispac liability, creating ambiguity in the liability decomposition. On liquidation, the full $5.5M is senior to equity. | ||||
| accounts_receivable | ||||
| Accounts Receivable Net Current total AccountsReceivableNetCurrent |
$1.64M | USD | ||
| AI Insight · AR of $1.6M at December 31, 2025, tagged as AccountsReceivableNetCurrent, is new versus the prior period (nil at September 30, 2025 based on prior filing). This likely represents amounts due under the Boehringer Ingelheim FTE reimbursement or milestone receivable. At 90-95% recovery haircut, recoverable value is approximately $1.5M. Counterparty is a large pharmaceutical company (BI), so credit quality is high and 90% haircut may be conservative, but the standard lens applies. | ||||
| Receivables Net Current total ReceivablesNetCurrent |
$2.00M | USD | ||
| AI Insight · A separate $2.0M receivable is tagged ReceivablesNetCurrent, distinct from the AR line. Based on context, this appears to be the milestone or upfront payment receivable from Boehringer Ingelheim. At 90-95% recovery, this contributes approximately $1.8M-$1.9M to liquidation proceeds. The filing does not separately narrate the nature of this specific balance in the notes reviewed; it may overlap with deferred revenue mechanics from the BI agreement. | ||||
| cash | ||||
| Cash And Cash Equivalents At Carrying Value total CashAndCashEquivalentsAtCarryingValue |
$14.48M | USD | ||
| AI Insight · Cash and equivalents of $14.5M at December 31, 2025, recover at 100% under the liquidation lens. This is a step-change from the prior filing period (September 30, 2025 cash of $1.3M), driven by the November 2025 public offering gross proceeds of approximately $18.2M ($16.9M net to company) plus warrant exercises of $1.5M in the six-month period. Cash is the dominant asset and the sole high-confidence recovery line. The Company's management asserts twelve-month going-concern adequacy based on this position. | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents total CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
$14.48M | USD | ||
| current_liabilities | ||||
| Accrued Liabilities Current total AccruedLiabilitiesCurrent |
$659,841 | USD | ||
| Operating Lease Liability Current total OperatingLeaseLiabilityCurrent |
$219,727 | USD | ||
| AI Insight · Current operating lease liability of $0.22M and noncurrent of $0.13M ($0.35M aggregate) remain on the balance sheet at December 31, 2025. Under the liquidation lens, these do not extinguish on wind-up and must be settled at face value. The corresponding ROU asset of $0.35M recovers at or near zero. The prior period (September 30, 2025) showed $0.13M current lease obligation; the current period shows $0.22M current, indicating the lease term is running down but ASC 842 classification shift is pushing more into current. Net liquidation impact is approximately negative $0.35M versus zero ROU recovery. | ||||
| Other Accrued Liabilities Current total OtherAccruedLiabilitiesCurrent |
$7,940 | USD | ||
| liabilities_current | ||||
| Liabilities Current total LiabilitiesCurrent |
$6.33M | USD | ||
| AI Insight · Total current liabilities of $6.3M include the $3.8M Altanispac deferred consideration per MD&A disclosure, which is not separately XBRL-tagged and appears embedded in AccountsPayableCurrent. On a December 31, 2025 liquidation snap, this full amount is a face-value claim against assets. The prior period current liabilities were $8.2M (per prior filing), so the headline number declined modestly despite the Altanispac liability being added, reflecting paydown of other obligations from operating cash. | ||||
| liabilities_total | ||||
| Liabilities total | $6.46M | USD | ||
| operating_lease_liability | ||||
| Operating Lease Liability Current fact OperatingLeaseLiabilityCurrent |
$219,727 | USD | ||
| AI Insight · Current operating lease liability of $0.22M and noncurrent of $0.13M ($0.35M aggregate) remain on the balance sheet at December 31, 2025. Under the liquidation lens, these do not extinguish on wind-up and must be settled at face value. The corresponding ROU asset of $0.35M recovers at or near zero. The prior period (September 30, 2025) showed $0.13M current lease obligation; the current period shows $0.22M current, indicating the lease term is running down but ASC 842 classification shift is pushing more into current. Net liquidation impact is approximately negative $0.35M versus zero ROU recovery. | ||||
| Operating Lease Liability Noncurrent fact OperatingLeaseLiabilityNoncurrent |
$129,061 | USD | ||
| shares_outstanding | ||||
| Common Stock Shares Outstanding total CommonStockSharesOutstanding |
1.8M | shares | ||
Unmapped Tags (67)
| Additional Paid In Capital AdditionalPaidInCapital | $473.11M | USD | ||
| Assets Assets | $17.93M | USD | ||
| Assets Current AssetsCurrent | $17.47M | USD | ||
| Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare | $0 | USD/shares | ||
| Common Stock Shares Authorized CommonStockSharesAuthorized | $300.00M | shares | ||
| Common Stock Shares Issued CommonStockSharesIssued | $1.76M | shares | ||
| Common Stock Value CommonStockValue | $17,572 | USD | ||
| Investment Income Net InvestmentIncomeNet | $83,668 | USD | ||
| Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity | $17.93M | USD | ||
| Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset | $346,764 | USD | ||
| Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare | $0 | USD/shares | ||
| Preferred Stock Shares Authorized PreferredStockSharesAuthorized | $10.00M | shares | ||
| Property Plant And Equipment Net PropertyPlantAndEquipmentNet | $113,485 | USD | ||
| Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit | $-461.66M | USD | ||
| Stockholders Equity StockholdersEquity | $11.47M | USD | ||
| AI Insight · Reported stockholders' equity of $11.5M reflects the substantial dilutive capital raise in November 2025 ($16.9M net common stock issuance tagged as StockIssuedDuringPeriodValueOther at $16.9M). This is up dramatically from the near-zero or negative equity implied by the September 30, 2025 balance (prior filing showed cash of $1.3M against current liabilities of $8.2M). Accumulated deficit stands at negative $461.7M, reflecting the company's history of losses. Under liquidation lens, book equity of $11.5M overstates actual recovery to common shareholders due to preferred liquidation preferences and the standard liquidation discount on non-cash assets. | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect | $11.91M | USD | ||
| Depreciation And Amortization DepreciationAndAmortization | $28,775 | USD | ||
| Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable | $-1.55M | USD | ||
| Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable | $1.64M | USD | ||
| Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities | $-221,571 | USD | ||
| Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability | $-63,711 | USD | ||
| Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables | $-29,468 | USD | ||
| Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | $972,381 | USD | ||
| Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities | $18.35M | USD | ||
| Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities | $-12,816 | USD | ||
| Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities | $-6.43M | USD | ||
| Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment | $12,816 | USD | ||
| Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock | $16.91M | USD | ||
| Proceeds From Warrant Exercises ProceedsFromWarrantExercises | $1.46M | USD | ||
| Share Based Compensation ShareBasedCompensation | $478,451 | USD | ||
| Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | $24,769 | shares | ||
| Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | $408 | USD/shares | ||
| Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod | $4,031 | shares | ||
| Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | $590 | shares | ||
| Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | $39,550 | shares | ||
| Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | $79,720 | shares | ||
| Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | $159 | USD/shares | ||
| Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber | $54,951 | shares | ||
| Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice | $47 | USD/shares | ||
| Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice | $488 | USD/shares | ||
| Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | $113 | USD/shares | ||
| Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | $21 | USD/shares | ||
| Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation | $478,451 | USD | ||
| Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | $8.59M | shares | ||
| Earnings Per Share Basic EarningsPerShareBasic | $-1 | USD/shares | ||
| Earnings Per Share Diluted EarningsPerShareDiluted | $-1 | USD/shares | ||
| General And Administrative Expense GeneralAndAdministrativeExpense | $4.79M | USD | ||
| Interest Expense Nonoperating InterestExpenseNonoperating | $2,500 | USD | ||
| Net Income Loss NetIncomeLoss | $-2.59M | USD | ||
| Operating Expenses OperatingExpenses | $11.63M | USD | ||
| Operating Income Loss OperatingIncomeLoss | $-2.67M | USD | ||
| Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense | $63,120 | USD | ||
| Other Nonoperating Income Expense OtherNonoperatingIncomeExpense | $81,168 | USD | ||
| Other Prepaid Expense Current OtherPrepaidExpenseCurrent | $349,630 | USD | ||
| Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets | $1.35M | USD | ||
| Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent | $1.35M | USD | ||
| Research And Development Expense ResearchAndDevelopmentExpense | $6.85M | USD | ||
| Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax | $8.96M | USD | ||
| Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation | $346,341 | USD | ||
| Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation | $300,000 | EUR | ||
| Accrued Professional Fees Current AccruedProfessionalFeesCurrent | $105,565 | USD | ||
| Depreciation Depreciation | $28,775 | USD | ||
| Interest Paid Net InterestPaidNet | $2,500 | USD | ||
| Number Of Operating Segments NumberOfOperatingSegments | $1 | Segment | ||
| Segment Reporting Other Item Amount SegmentReportingOtherItemAmount | $-81,168 | USD | ||
| Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther | $16.91M | USD | ||
| AdministrativeFeesExpense AdministrativeFeesExpense | $3.08M | USD | ||
Showing balance sheet tags only. Liquidation analysis uses balance sheet data.